|Bid||170.03 x 2000|
|Ask||184.80 x 1900|
|Day's Range||177.07 - 178.78|
|52 Week Range||147.08 - 179.05|
|PE Ratio (TTM)||-29.74|
|Expense Ratio (net)||0.09%|
Abiomed is primarily focused on the growth opportunity in the protected PCI area, a procedure that is applicable for patients with coronary artery disease.
In March 2017, Abiomed (ABMD) submitted premarket approval (or PMA) to the FDA for its Impella RP device far ahead of schedule.
PTEN's management believes that its merger with Seventy Seven Energy has consolidated PTEN’s position in drilling and pressure pumping activity.